Trial watch: Peptide-based vaccines in anticancer therapy

Trial watch: Peptide-based vaccines in anticancer therapy

Peptide-based anticancer vaccination aims at stimulating an immune response against one or multiple tumor-associated antigens (TAAs) following immunization with purified, recombinant or synthetically engineered epitopes. Despite high expectations, the peptide-based vaccines that have been explored i...

Full description

Bibliographic Details
Main Authors:	Lucillia Bezu, Oliver Kepp, Giulia Cerrato, Jonathan Pol, Jitka Fucikova, Radek Spisek, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2018-12-01
Series:	OncoImmunology
Subjects:	car t cells immune checkpoint blockers magea3 mutational load ny-eso-1 synthetic long peptides tumor neoantigens
Online Access:	http://dx.doi.org/10.1080/2162402X.2018.1511506

Similar Items

Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology
by: Isaure Vanmeerbeek, et al.
Published: (2020-01-01)

Trial Watch: Adoptively transferred cells for anticancer immunotherapy
by: Carole Fournier, et al.
Published: (2017-11-01)

Trial watch: IDO inhibitors in cancer therapy
by: Julie Le Naour, et al.
Published: (2020-01-01)

Immune landscape and in vivo immunogenicity of NY-ESO-1 tumor antigen in advanced neuroblastoma patients
by: Chiara Camisaschi, et al.
Published: (2018-10-01)

Trial watch: Dendritic cell-based anticancer immunotherapy
by: Abhishek D. Garg, et al.
Published: (2017-07-01)

Trial watch: TLR3 agonists in cancer therapy
by: Julie Le Naour, et al.
Published: (2020-01-01)

Trial watch: dietary interventions for cancer therapy
by: Sarah Lévesque, et al.
Published: (2019-07-01)

NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives
by: Remy Thomas, et al.
Published: (2018-05-01)

Trial watch: STING agonists in cancer therapy
by: Julie Le Naour, et al.
Published: (2020-01-01)

Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics
by: Abhishek D. Garg, et al.
Published: (2017-12-01)

Differential expression of MAGEA6 toggles autophagy to promote pancreatic cancer progression
by: Yiu Huen Tsang, et al.
Published: (2020-04-01)

Trial Watch: experimental TLR7/TLR8 agonists for oncological indications
by: Giorgio Frega, et al.
Published: (2020-01-01)

Unleashing the immune response to NY-ESO-1 cancer testis antigen as a potential target for cancer immunotherapy
by: Afsheen Raza, et al.
Published: (2020-03-01)

Trial watch: dendritic cell vaccination for cancer immunotherapy
by: Jenny Sprooten, et al.
Published: (2019-11-01)

Trial watch: Immune checkpoint blockers for cancer therapy
by: Claire Vanpouille-Box, et al.
Published: (2017-11-01)

Squamous Cell Carcinomas of the Head and Neck Cancer Response to Programmed Cell Death Protein-1 Targeting and Differential Expression of Immunological Markers: A Case Report
by: Maysaloun Merhi, et al.
Published: (2018-07-01)

Tumor LAG‐3 and NY‐ESO‐1 expression predict durable clinical benefits of immune checkpoint inhibitors in advanced non‐small cell lung cancer
by: Eun Hee Jung, et al.
Published: (2021-03-01)

Generated SecPen_NY-ESO-1_ubiquitin-pulsed dendritic cell cancer vaccine elicits stronger and specific T cell immune responses
by: Yunkai Yang, et al.
Published: (2021-02-01)

Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma
by: Indu Ramachandran, et al.
Published: (2019-10-01)

Plant Viral Nanoparticle-based Vaccine Targeting NY-ESO-1+ Triple Negative Breast Cancer
by: Patel, Bindi, Patel
Published: (2018)

Upregulation of MAGEA4 correlates with poor prognosis in patients with early stage of esophageal squamous cell carcinoma
by: Tang WW, et al.
Published: (2016-07-01)

Adoptive Cell Therapy Targeting Neoantigens: A Frontier for Cancer Research
by: Zhidong Wang, et al.
Published: (2020-03-01)

Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy
by: Elena García-Martínez, et al.
Published: (2018-06-01)

Evaluation of Production Protocols for the Generation of NY-ESO-1-Specific T Cells
by: Wenjie Gong, et al.
Published: (2021-01-01)

Adjuvant NY-ESO-1 vaccine immunotherapy in high-risk resected melanoma: a retrospective cohort analysis
by: Michael Lattanzi, et al.
Published: (2018-05-01)

Guillain-Barre syndrome observed with adoptive transfer of lymphocytes genetically engineered with an NY-ESO-1 reactive T-cell receptor
by: Jocelyn Joseph, et al.
Published: (2019-11-01)

Prevalence of plasma autoantibody against cancer testis antigen NY-ESO-1 in HTLV-1 infected individuals with different clinical status
by: Yasuo Shiohama, et al.
Published: (2017-07-01)

Trial Watch: Toll-like receptor agonists in cancer immunotherapy
by: Melody Smith, et al.
Published: (2018-12-01)

The Co-Expression of Melanoma-Antigen Family a Proteins and New York Esophageal Squamous Cell Carcinoma-1 in Breast Cancer: A Pilot Study
by: Wang YX, et al.
Published: (2021-08-01)

MAGE-A3/4 and NY-ESO-1 antigens expression in metastatic esophageal squamous cell carcinoma
by: T. Bujas, et al.
Published: (2011-03-01)

MAGE-A4, NY-ESO-1 and SAGE mRNA expression rates and co-expression relationships in solid tumours
by: Mikiya Ishihara, et al.
Published: (2020-06-01)

Lurbinectedin: an FDA-approved inducer of immunogenic cell death for the treatment of small-cell lung cancer
by: Oliver Kepp, et al.
Published: (2020-01-01)

Knockdown of MAGEA6 Activates AMP-Activated Protein Kinase (AMPK) Signaling to Inhibit Human Renal Cell Carcinoma Cells
by: Xueting Ye, et al.
Published: (2018-02-01)

Novel strategies for immuno-oncology breakthroughs with cell therapy
by: Hongtao Liu, et al.
Published: (2021-07-01)

Cancer Testis Antigens and Immunotherapy: Expression of PRAME Is Associated with Prognosis in Soft Tissue Sarcoma
by: Markus Albertsmeier, et al.
Published: (2020-12-01)

The intestinal microbiota determines the clinical efficacy of immune checkpoint blockers targeting PD-1/PD-L1
by: Lisa Derosa, et al.
Published: (2018-06-01)

Epigenetic Upregulation of MAGE-A Isoforms Promotes Breast Cancer Cell Aggressiveness
by: Chaeun Oh, et al.
Published: (2021-06-01)

Expression of tumor-associated antigens in breast cancer subtypes
by: Giuseppe Curigliano, et al.
Published: (2020-02-01)

Prognostic impact of p53 and/or NY‐ESO‐1 autoantibody induction in patients with gastroenterological cancers
by: Isamu Hoshino, et al.
Published: (2020-05-01)

CD103+ cells at the forefront of anticancer immunity
by: Claire Vanpouille-Box, et al.
Published: (2017-11-01)